期刊论文详细信息
Frontiers in Immunology
Identification of SKOR2 IgG as a novel biomarker of paraneoplastic neurologic syndrome
Immunology
Ronak K. Kapadia1  Reghann G. LaFrance-Corey2  Andrew M. Knight2  Yong Guo3  Mohamed Rezk4  John R. Mills4  Surendra Dasari4  Pranjal Gupta4  Divyanshu Dubey5  Andrew McKeon5  Sean J. Pittock5  Anastasia Zekeridou5 
[1] Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada;Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States;Department of Neurology, Mayo Clinic, Rochester, MN, United States;Department of Neurology, Mayo Clinic, Rochester, MN, United States;Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States;Department of Neurology, Mayo Clinic, Rochester, MN, United States;Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States;Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, United States;
关键词: paraneoplastic neurologic syndrome;    paraneoplastic encephalitis;    antibody biomarker;    gall bladder adenocarcinoma;    lung adecarcinoma;   
DOI  :  10.3389/fimmu.2023.1243946
 received in 2023-06-21, accepted in 2023-08-22,  发布年份 2023
来源: Frontiers
PDF
【 摘 要 】

IntroductionThe development of new autoantigen discovery techniques, like programmable phage immunoprecipitation sequencing (PhIP-Seq), has accelerated the discovery of neural-specific autoantibodies. Herein, we report the identification of a novel biomarker for paraneoplastic neurologic syndrome (PNS), Sloan-Kettering-Virus-Family-Transcriptional-Corepressor-2 (SKOR2)-IgG, utilizing PhIP-Seq. We have also performed a thorough clinical validation using normal, healthy, and disease/cancer control samples.MethodsStored samples with unclassified staining at the junction of the Purkinje cell and the granule cell layers were analyzed by PhIP-Seq for putative autoantigen identification. The autoantigen was confirmed by recombinant antigen-expressing cell-based assay (CBA), Western blotting, and tissue immunofluorescence assay colocalization.ResultsPhIP-Seq data revealed SKOR2 as the candidate autoantigen. The target antigen was confirmed by a recombinant SKOR-2-expressing, and cell lysate Western blot. Furthermore, IgG from both patient samples colocalized with a commercial SKOR2–specific IgG on cryosections of the mouse brain. Both SKOR2 IgG-positive patients had central nervous system involvement, one presenting with encephalitis and seizures (Patient 1) and the other with cognitive dysfunction, spastic ataxia, dysarthria, dysphagia, and pseudobulbar affect (Patient 2). They had a refractory progressive course and were diagnosed with adenocarcinoma (Patient 1: lung, Patient 2: gallbladder). Sera from adenocarcinoma patients without PNS (n=30) tested for SKOR2-IgG were negative.DiscussionSKOR2 IgG represents a novel biomarker for PNS associated with adenocarcinoma. Identification of additional SKOR2 IgG-positive cases will help categorize the associated neurological phenotype and the risk of underlying malignancy.

【 授权许可】

Unknown   
Copyright © 2023 Rezk, Pittock, Kapadia, Knight, Guo, Gupta, LaFrance-Corey, Zekeridou, McKeon, Dasari, Mills and Dubey

【 预 览 】
附件列表
Files Size Format View
RO202310125947201ZK.pdf 5704KB PDF download
  文献评价指标  
  下载次数:20次 浏览次数:0次